ALNY Alnylam Pharmaceuticals Inc

USD 224.91 -1.49 (-0.66%)
At close: 04:00PM EST
Icon

Alnylam Pharmaceuticals Inc Stock Analysis and Price Target COMMON STOCK | Biotechnology | NSD

stockTargetAdvisor

Buy

Average User
Rating
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis

USD 224.91

-1.49 (-0.66)%

USD 27.73B

0.75M

USD 232.48(+3.37%)

USD 198.25 (-11.85%)

Icon

ALNY

Alnylam Pharmaceuticals Inc (USD)
COMMON STOCK | NSD
USD 224.91
-1.49 (-0.66%)
At close: 04:00PM EST
stockTargetAdvisor

Buy

Average User
Rating
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis

USD 27.73B

USD 198.25 (-11.85%)

USD 224.91

Alnylam Pharmaceuticals Inc Stock Forecast

USD 232.48
(+3.37%)

Based on the Alnylam Pharmaceuticals Inc stock forecasts from 18 analysts, the average analyst target price for Alnylam Pharmaceuticals Inc is USD 232.48 over the next 12 months. Alnylam Pharmaceuticals Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Alnylam Pharmaceuticals Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Alnylam Pharmaceuticals Inc’s stock price was USD 224.91. Alnylam Pharmaceuticals Inc’s stock price has changed by -1.79% over the past week, -5.36% over the past month and +55.19% over the last year.

No recent analyst target price found for Alnylam Pharmaceuticals Inc
No recent average analyst rating found for Alnylam Pharmaceuticals Inc

Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metaboli...Read More

https://www.alnylam.com

675 West Kendall Street, Cambridge, MA, United States, 02142

1,665

December

USD

USA

Adjusted Closing Price

Loading...

Technical Indicators

  • 0.50

  • USD 242.97

  • 8.10

  • USD 117.58

  • 5,679,258

  • USD 187.48

  • 5,112,936

  • USD 227.22

  • 0.54%

  • 5.42%

  • 100.91%

  • N/A

Unadjusted Closing Price

Loading...

Assets

Top Holdings

Top Sectors

Top Regions

Share Volume

Loading...

Relative Performance

Security Capital Gain Dividend Return Total Return
Loading...

Stocks Similar To Alnylam Pharmaceuticals Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -5.83 (-1.80%) USD82.14B 25.24 16.84
REGN
Regeneron Pharmaceuticals Inc -0.47 (-0.06%) USD80.20B 15.52 12.07
MRNA
Moderna Inc -1.76 (-1.00%) USD67.64B 6.64 5.34
ALXN
Alexion Pharmaceuticals Inc 0.00 (0.00%) USD40.34B 59.23 42.56
BNTX
BioNTech SE -0.36 (-0.25%) USD34.86B 3.27 2.14
BGNE
BeiGene Ltd -1.72 (-0.67%) USD26.95B N/A -9.58
SGEN
Seagen Inc -0.45 (-0.32%) USD25.90B 55.02 -38.86
GMAB
Genmab AS -0.03 (-0.08%) USD25.68B 30.85 3.59
BMRN
Biomarin Pharmaceutical Inc +1.36 (+1.18%) USD21.32B 266.74 90.91
ARGX
argenx NV ADR -2.52 (-0.66%) USD21.13B N/A -21.25

ETFs Containing ALNY

Symbol Name Weight Mer Price(Change) Market Cap
MSGR
Direxion mRNA ETF 6.57 % 0.65 % +0.18 (+1.16%) USD4.43M
GERM
ETFMG Treatments Testing .. 6.06 % 0.68 % -0.10 (-0.40%) USD0.02B
GNOM
Global X Genomics & Biote.. 4.28 % 0.50 % +0.22 (+1.62%) USD0.23B
UTRN
Vesper U.S. Large Cap Sho.. 4.02 % 0.75 % +0.02 (+0.08%) USD0.07B
BIOT:SW
L&G Pharma Breakthrough U.. 3.25 % 0.00 % -0.06 (-0.54%) N/A
ETLI:XETRA
L&G Pharma Breakthrough U.. 3.25 % 0.49 % -0.10 (-0.93%) USD0.04B
ETLI:F
Legal & General UCITS ETF.. 3.25 % 0.49 % -0.11 (-0.95%) USD0.04B
BTEC
Principal Healthcare Inno.. 3.17 % 0.42 % +0.35 (+0.96%) USD0.06B
QQQN
VictoryShares Nasdaq Next.. 3.15 % 0.18 % +0.68 (+2.61%) USD0.10B
IBBQ
Invesco Nasdaq Biotechnol.. 2.59 % 0.19 % -0.01 (-0.05%) USD0.02B
IBB
iShares Biotechnology ETF 2.58 % 0.44 % +0.16 (+0.12%) USD8.94B
BTEK:LSE
iShares Nasdaq US Biotech.. 2.56 % 0.35 % -0.05 (-1.03%) USD0.47B
BTEE:LSE
iShares Nasdaq US Biotech.. 2.56 % 0.35 % -0.07 (-1.10%) USD0.04B
BTEC:LSE
iShares Nasdaq US Biotech.. 2.56 % 0.35 % -0.07 (-1.14%) USD0.47B
QQQJ
Invesco NASDAQ Next Gen 1.. 1.97 % 0.15 % +0.53 (+2.02%) USD0.81B
TMFX
Motley Fool Next Index ET.. 1.81 % 0.50 % +0.20 (+1.30%) USD0.03B
RBUS
Nationwide Risk-Based U.S.. 0.71 % 0.30 % 0.00 (0.00%) USD0.11B
ETHO
Etho Climate Leadership U.. 0.57 % 0.47 % +0.99 (+1.84%) USD0.18B

Frequently Asked Questions About ALNY Stock

Based on ratings from 18 analysts Alnylam Pharmaceuticals Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 9 buy, sell and 10 hold ratings.

Unfortunately we do not have enough data on ALNY's stock to indicate if its a good dividend stock.

Based on targets from 18 analysts, the average taret price for ALNY is USD 232.48 over the next 12 months. The maximum analyst target price is USD 415 while the minimum anlayst target price is USD 143.

Unfortunately we do not have enough data on ALNY's stock to indicate if its overvalued.

The last closing price of ALNY's stock was USD 224.91.

The most recent market capitalization for ALNY is USD 27.73B.

Based on targets from 18 analysts, the average taret price for ALNY is projected at USD 232.48 over the next 12 months. This means that ALNY's stock price may go up by +3.37% over the next 12 months.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...